Longboard pharmaceuticals to host investor & analyst event in new york on september 16, 2024

La jolla, calif.--(business wire)---- $lbph #epilepsy--longboard pharmaceuticals, inc. (nasdaq: lbph), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it will host an investor & analyst event which will feature updates for the planned global phase 3 program evaluating bexicaserin (lp352), a first-in-class 5-ht2c receptor superagonist in development for the treatment of seizures associated with developmental and epi.
LBPH Ratings Summary
LBPH Quant Ranking